Literature DB >> 1546447

V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity.

L A Ivanoff1, J W Dubay, J F Morris, S J Roberts, L Gutshall, E J Sternberg, E Hunter, T J Matthews, S R Petteway.   

Abstract

The mechanism by which HIV-1 mediates cell fusion and penetrates target cells, subsequent to receptor (CD4) binding, is not well understood. However, neutralizing antibodies, which recognize the principal neutralizing determinants of the gp120 envelope protein (the V3 loop region, residues 296 to 331), have been shown to effectively block cell fusion and virus infectivity independent of the initial gp120-CD4 binding. To investigate the role of the V3 loop in an HIV infection, a series of site-specific mutations were introduced into the HIV-1 envelope gene. Specifically, each residue (312 to 315) in the strongly conserved tetrapeptide sequence, GPGR, which is positioned in the center of the V3 loop domain was individually altered. The processing, transport, and CD4 binding properties of the mutant envelope proteins were comparable to those of the wild-type protein, however, none of the mutants were able to form syncytia in the HeLa-T4 assay. Molecular HIV-1 clones containing mutations altering the G312, G314, or R315 residues produced noninfectious virions, whereas a clone with a P313A mutation was found to be infectious. These results demonstrate that certain V3 loop mutations can be lethal and clearly indicate that this region of the HIV-1 gp120 protein is essential for virus infectivity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546447     DOI: 10.1016/0042-6822(92)90444-t

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  33 in total

Review 1.  How does HIV-1 infect a susceptible human cell?: Current thinking.

Authors:  Ali A Al-Jabri
Journal:  J Sci Res Med Sci       Date:  2003-08

2.  Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion.

Authors:  L Picard; G Simmons; C A Power; A Meyer; R A Weiss; P R Clapham
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

Review 3.  Virus receptors: implications for pathogenesis and the design of antiviral agents.

Authors:  L C Norkin
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

4.  Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.

Authors:  M Schreiber; H Petersen; C Wachsmuth; H Müller; F T Hufert; H Schmitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

Review 5.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

6.  Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release.

Authors:  E A Berger; J R Sisler; P L Earl
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

7.  Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.

Authors:  Preetha Balasubramanian; Rajnish Kumar; Constance Williams; Vincenza Itri; Shixia Wang; Shan Lu; Ann J Hessell; Nancy L Haigwood; Faruk Sinangil; Keith W Higgins; Lily Liu; Liuzhe Li; Phillipe Nyambi; Miroslaw K Gorny; Maxim Totrov; Arthur Nadas; Xiang-Peng Kong; Susan Zolla-Pazner; Catarina E Hioe
Journal:  Vaccine       Date:  2017-02-06       Impact factor: 3.641

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope.

Authors:  S Lombardi; C Garzelli; C La Rosa; L Zaccaro; S Specter; G Malvaldi; F Tozzini; F Esposito; M Bendinelli
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  Rabbit anti-HIV-1 monoclonal antibodies raised by immunization can mimic the antigen-binding modes of antibodies derived from HIV-1-infected humans.

Authors:  Ruimin Pan; Jared M Sampson; Yuxin Chen; Michael Vaine; Shixia Wang; Shan Lu; Xiang-Peng Kong
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.